This index provides comprehensive coverage of diagnostic methods, biomarkers, and assessment tools for neurodegenerative diseases. The diagnostics section covers established clinical diagnostics, emerging biomarkers, imaging techniques, and novel detection methods for Alzheimer's disease, Parkinson's disease, and related disorders.
Early and accurate diagnosis of neurodegenerative diseases is critical for effective treatment, clinical trial enrollment, and patient care. The field has seen remarkable advances in biomarkers, imaging, and digital health technologies that enable detection of pathology years before clinical symptoms appear.
This index currently lists 19 published diagnostics pages covering the full spectrum of diagnostic approaches from CSF biomarkers to digital phenotypes.
Fluid biomarkers analyze cerebrospinal fluid (CSF), blood, or other bodily fluids to detect disease-related proteins and molecules:
The most significant recent advance in neurodegeneration diagnostics is the development of blood-based biomarkers:
- Aβ42/40 Ratio: Plasma Aβ ratio predicts amyloid PET positivity
- p-tau181/tau217: Highly specific for AD pathology
- NfL (Neurofilament Light Chain): Marker of neuroaxonal injury
- α-synuclein seeds: Detection in blood using RT-QuIC
- Gait Analysis: Smartphones and wearable accelerometers
- Voice Analysis: Speech pattern changes in PD and AD
- Typing Dynamics: Keyboard interaction patterns
- Sleep Monitoring: REM sleep behavior disorder detection
- Combination Biomarker Panels: Integrating fluid, imaging, and digital markers
- Machine Learning Models: AI-driven diagnosis from multimodal data
- Precision Medicine: Personalized diagnostic approaches
- Amyloid Biomarkers: CSF Aβ42, plasma Aβ, amyloid PET
- Tau Biomarkers: CSF p-tau, tau PET
- Neurodegeneration Markers: CSF total tau, NfL
- Clinical Assessment: MMSE, MoCA, CDR
- α-Synuclein Assays: RT-QuIC, PMCA
- Dopaminergic Imaging: DaTscan, FDOPA PET
- Clinical Criteria: UK Brain Bank criteria
- Digital Markers: Movement analysis, smell tests
- Neurophysiology: EMG, nerve conduction studies
- Fluid Biomarkers: NfL, pNfH, GFAP
- Genetic Testing: SOD1, C9orf72, FUS
- Neuroimaging: Frontotemporal atrophy patterns
- Fluid Biomarkers: Progranulin, p-tau, NfL
- Neuropsychological Testing: Language and behavior assessments
- Sensitivity vs. Specificity Trade-offs: Early detection often comes with false positives
- Access to Specialized Testing: PET, CSF analysis not universally available
- Cost: Advanced biomarkers remain expensive
- Standardization: Inter-laboratory variability in biomarker assays
- Population Screening: Implementing diagnostic testing in general population
- Primary Care Integration: Simplified tests for wider availability
- Point-of-Care Testing: Rapid, bedside diagnostic methods
- Prevention Trials: Identifying pre-symptomatic individuals
-
Jack CR Jr, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
-
Postuma RB, et al. MDS clinical criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601.
-
Ludolph AC, et al. EFNS guidelines on the clinical management of ALS. J Neurol. 2015;262(10):2155-2168.
-
Rascovsky K, et al. Diagnostic criteria for behavioural variant FTD. Brain. 2011;134(9):2456-2477.
-
Blennow K, et al. Cerebrospinal fluid biomarkers in neurodegenerative diseases. Nat Rev Neurol. 2011;7(5):251-260.
-
Zetterberg H, et al. Neurofilament light chain in CSF and blood. Ann Neurol. 2019;86(2):218-224.